{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:00:28Z","timestamp":1790625628345,"version":"4.1.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Myasthenia gravis (MG) is a heterogeneous disorder whose clinical presentation ranges from mild ocular deficits to severe widespread weakness. This variance poses a challenge when quantifying clinical deficits. Deficits and symptoms are quantified using standardized clinical scales and questionnaires which are often used as outcome measures. The past decades have seen the development of several validated outcome measures in MG, which are used in clinical trials to obtain regulatory approval. In recent years, emphasis has moved from objective assessments to patient-reported outcomes. Despite a growing body of literature on the validity of the MG-specific outcome measures, several unresolved factors remain. As several novel therapeutics are currently in clinical development, knowledge about capabilities and limitations of outcome measures is needed. In the present paper, we describe the most widely used clinical classifications and scales in MG. We highlight the choice of outcome measures in published and ongoing trials, and we denote whether trial efficacy was reached on these outcomes. We discuss advantages and limitations of the individual scales, and discuss some of the unresolved factors relating to outcome assessments in MG.<\/jats:p>","DOI":"10.3389\/fneur.2020.596382","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T03:55:47Z","timestamp":1608695747000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":71,"title":["Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis"],"prefix":"10.3389","volume":"11","author":[{"given":"Jan Lykke Scheel","family":"Thomsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve."},{"key":"B3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/archinte.1958.00260190074008","article-title":"Studies in myasthenia gravis: review of two hundred eighty-two cases at The Mount Sinai Hospital, New York City","volume":"102","author":"Osserman","year":"1958","journal-title":"AMA Arch Int Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/0022-510X(64)90171-6","article-title":"Studies in myasthenia gravis. Part 1. A clinical study of 180 patients","volume":"1","author":"Oosterhuis","year":"1964","journal-title":"J Neurol Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteriod treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF00314245","article-title":"Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis","volume":"235","author":"Mantegazza","year":"1988","journal-title":"J Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1196\/annals.1254.057","article-title":"A simple manual muscle test for myasthenia gravis","volume":"998","author":"Sanders","year":"2003","journal-title":"Ann N Y Acad Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/jama.1930.27120410003009c","article-title":"A report of progress on the use of ephedrine in a case of myasthenia gravis","volume":"94","author":"Edgeworth","year":"1930","journal-title":"J Am Med Assoc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S0140-6736(00)94294-6","article-title":"Treatment of myasthenia gravis with physostigmine","volume":"223","author":"Walker","year":"1934","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1001\/jama.1935.02760230013004","article-title":"Myasthenia gravis: effect of treatment with anterior pituitary extract: preliminary report","volume":"104","author":"Simon","year":"1935","journal-title":"J Am Med Assoc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/00000658-193910000-00005","article-title":"Myasthenia gravis and tumors of the thymic region","volume":"110","author":"Blalock","year":"1939","journal-title":"Ann Surg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","article-title":"Measuring clinical treatment response in myasthenia gravis","volume":"36","author":"Barnett","year":"2018","journal-title":"Neurol Clin."},{"key":"B14","first-page":"939","article-title":"[Long-term effects of plasma exchange in myasthenia. Results of a randomized study]","volume":"12","author":"Gajdos","year":"1983","journal-title":"Presse Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"New Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis scorea","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s100720200027","article-title":"Myasthenia gravis outcome measure: development and validation of a disease-specific self-administered questionnaire","volume":"23","author":"Padua","year":"2002","journal-title":"Neurol Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awl095","article-title":"MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis","volume":"129","author":"Farrugia","year":"2006","journal-title":"Brain."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/mus.21185","article-title":"Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve."},{"key":"B21","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mus.21016","article-title":"Disease-specific measure of quality of life for myasthenia gravis","volume":"38","author":"Mullins","year":"2008","journal-title":"Muscle Nerve."},{"key":"B22","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve."},{"key":"B24","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3109\/09638288.2013.804591","article-title":"Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis","volume":"36","author":"Raggi","year":"2014","journal-title":"Disabil Rehabil."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/mus.21713","article-title":"History of outcome measures for myasthenia gravis","volume":"42","author":"Burns","year":"2010","journal-title":"Muscle Nerve."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/JND-150082","article-title":"Psychometric properties of the quantitative myasthenia gravis score and the myasthenia gravis composite scale","volume":"2","author":"Barnett","year":"2015","journal-title":"J Neuromusc Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s004150050585","article-title":"Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis","volume":"247","author":"Sharshar","year":"2000","journal-title":"J Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.21883","article-title":"The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis","volume":"43","author":"Burns","year":"2011","journal-title":"Muscle Nerve."},{"key":"B33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"New Engl J Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther Adv Neurol Disord."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology."},{"key":"B46","first-page":"92","article-title":"Proof-of-concept and safety of the anti-FcRn antibody rozanolixizumab in patients with moderate-to-severe generalized myasthenia gravis (GMG): a phase 2a study (S43.001)","author":"Bril","year":"2019","journal-title":"Neurology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1196\/annals.1254.064","article-title":"Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study","volume":"998","author":"Meriggioli","year":"2003","journal-title":"Ann N Y Acad Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jns.2008.09.033","article-title":"Terbutaline in myasthenia gravis: a pilot study","volume":"277","author":"Soliven","year":"2009","journal-title":"J Neurol Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve."},{"key":"B50","doi-asserted-by":"publisher","first-page":"E1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology."},{"key":"B51","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis","volume":"7026","author":"Duda","year":"2020","journal-title":"JAMA Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/cen3.12174","article-title":"Quality of life measures for myasthenia gravis and evaluation of non-motor symptoms","volume":"6","author":"Jones","year":"2015","journal-title":"Clin Exp Neuroimmunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e00538","DOI":"10.1002\/brb3.538","article-title":"Fatigue in myasthenia gravis: risk factors and impact on quality of life","volume":"6","author":"Hoffmann","year":"2016","journal-title":"Brain Behav."},{"key":"B54","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","article-title":"The MG-QOL15 Japanese version: validation and associations with clinical factors","volume":"46","author":"masuda","year":"2012","journal-title":"Muscle Nerve."},{"key":"B55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1477-7525-8-129","article-title":"Quality of life and life circumstances in German myasthenia gravis patients","volume":"8","author":"Twork","year":"2010","journal-title":"Health Qual Life Outcomes."},{"key":"B56","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/mus.25720","article-title":"The utility of a single simple question in the evaluation of patients with myasthenia gravis","volume":"57","author":"Abraham","year":"2018","journal-title":"Muscle Nerve."},{"key":"B57","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","article-title":"Development and validation of the myasthenia gravis impairment index","volume":"87","author":"Barnett","year":"2016","journal-title":"Neurology."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1212\/WNL.0000000000004676","article-title":"Myasthenia gravis impairment index: responsiveness, meaningful change, and relative efficiency","volume":"89","author":"Barnett","year":"2017","journal-title":"Neurology."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e98089","DOI":"10.1371\/journal.pone.0098089","article-title":"A conceptual framework for evaluating impairments in myasthenia gravis","volume":"9","author":"Barnett","year":"2014","journal-title":"PLoS ONE."},{"key":"B60","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.nmd.2013.02.008","article-title":"Performance of individual items of the quantitative myasthenia gravis score","volume":"23","author":"Barnett","year":"2013","journal-title":"Neuromusc Disord."},{"key":"B61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3233\/JND-200484","article-title":"Myasthenia gravis impairment index: sensitivity for change in generalized muscle weakness","volume":"7","author":"de Meel","year":"2020","journal-title":"J Neuromusc Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/mus.26469","article-title":"The placebo response in myasthenia gravis assessed by quantitative myasthenia gravis score: a meta-analysis","volume":"59","author":"Frisaldi","year":"2019","journal-title":"Muscle Nerve."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/WNL.0000000000010574","article-title":"Patient-acceptable symptom states in myasthenia gravis","volume":"95","author":"Mendoza","year":"2020","journal-title":"Neurology."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/mus.21142","article-title":"Comparison of outcome measures from a trial of Mycophenolate mofetil in myasthenia gravis","volume":"38","author":"Wolfe","year":"2008","journal-title":"Muscle Nerve."},{"key":"B65","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CND.0000000000000257","article-title":"Impact of refractory myasthenia gravis on health-related quality of life","volume":"20","author":"Boscoe","year":"2019","journal-title":"J Clin Neuromusc Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mus.26114","article-title":"Burden of illness in patients with treatment refractory myasthenia gravis","volume":"58","author":"Engel-Nitz","year":"2018","journal-title":"Muscle Nerve."},{"key":"B68","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/mus.26069","article-title":"Fatigue is a relevant outcome in patients with myasthenia gravis","volume":"58","author":"Tran","year":"2018","journal-title":"Muscle Nerve"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual Life Res."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.596382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T03:55:49Z","timestamp":1608695749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.596382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":69,"alternative-id":["10.3389\/fneur.2020.596382"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.596382","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,23]]},"article-number":"596382"}}